当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Maintaining quality of life for patients with neuroendocrine tumours
The Lancet Oncology ( IF 51.1 ) Pub Date : 2017-08-21 , DOI: 10.1016/s1470-2045(17)30618-6
Thomas Walter

Ideally, new treatments should either improve overall survival or the health-related quality of life (HRQOL) of patients, or both, and should have a favourable cost-to-benefit ratio. For instance, FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) significantly improves progression-free survival, overall survival, and HRQOL compared with gemcitabine in patients with metastatic pancreatic adenocarcinoma, even though it causes substantially more side-effects.1,2 After publication of the RADIANT-3 and RADIANT-4 randomised, placebo-controlled, phase 3 studies, everolimus was approved for all non-functional, advanced, neuroendocrine tumours (NETs), including those of the pancreas,3 lung, and gastrointestinal tract,4 and sunitinib has been approved for pancreatic NETs (pNETs).

中文翻译:

维持神经内分泌肿瘤患者的生活质量

理想情况下,新疗法应改善患者的总体生存率或与健康相关的生活质量(HRQOL),或两者兼而有之,并应具有有利的成本效益比。例如,与吉西他滨相比,FOLFIRINOX(亚叶酸钙,氟尿嘧啶,伊立替康和奥沙利铂)与吉西他滨相比可显着改善无进展生存期,总生存期和HRQOL,尽管它引起的副作用更大。1,2在RADIANT-3和RADIANT-4随机,安慰剂对照的3期研究发表后,依维莫司被批准用于所有无功能的晚期神经内分泌肿瘤(NETs),包括胰腺,3肺,和胃肠道,4 sunitinib已获准用于胰腺NET(pNET)。
更新日期:2017-08-22
down
wechat
bug